News Quantified

ABUS – arbutus biopharma corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]

Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.

Arbutus Biopharma GAAP EPS of -$0.04 misses by $0.01, revenue of $0.53M misses by $0.42M [Seeking Alpha]

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

0.6%

BEAT

-4.0%

MISS

0.9%

MISS

0.9%

MISS

Chardan Capital

Chardan Capital

Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Nguyen Tuan

Form 4 Arbutus Biopharma Corp For: Feb 02 Filed by: Androski Lindsay

Form 8-K Arbutus Biopharma Corp For: Jan 15

Form 8-K Arbutus Biopharma Corp For: Dec 11

Form 8-K Arbutus Biopharma Corp For: Nov 13

Top News Gainers

6/20 Arbutus receives clearance to initiate early-stage AB-729 trial; shares up 8% premarket [Seeking Alpha] 32.6%

6/17 Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. 24.7%

2/10 Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer 20.6%

10/4 Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. 13.3%

2/27 Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results 10.7%

11/4 We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate [Yahoo! Finance News] 5.1%

5/20 Form 8-K Arbutus Biopharma Corp For: May 20 4.9%

7/3 Form 8-K Arbutus Biopharma Corp For: Jul 02 4.2%

7/12 Form 4 Arbutus Biopharma Corp For: Jul 10 Filed by: SVF Holdings (UK) LLP 4.0%

8/5 Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.1%

Top News Decliners

3/26 Form 8-K Arbutus Biopharma Corp For: Mar 26 -47.4%

10/3 Form 8-K Arbutus Biopharma Corp For: Oct 03 -28.7%

10/7 Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target lowered by analysts at B. Riley from $7.00 to $3.00. They now have a "buy" rating on the stock. -16.0%

7/15 Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha] -12.5%

7/18 Form 8-K Arbutus Biopharma Corp For: Jul 15 -11.3%

8/9 Form 8-K Arbutus Biopharma Corp For: Aug 09 -8.5%

5/13 Arbutus to Present at Upcoming May 2019 Conferences -7.9%

3/6 Form 10-K/A Arbutus Biopharma Corp For: Dec 31 -7.1%

5/28 Form 8-K Arbutus Biopharma Corp For: May 22 -6.9%

9/26 Arbutus to Participate in Upcoming Investor Conferences -6.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day